ClinicalTrials.gg
RecruitingNCT07018557PRYSMA-HTNUpdated Jun 12, 2025

Impact of Eszopiclone on Blood Pressure in Patients With Insomnia and Hypertension (PRYSMA-HTN)

A Phase 4 interventional study of Eszopiclone 3 mg and Placebo in Insomnia and Hypertension, sponsored by University of Sao Paulo. Recruiting at 1 site in Brazil. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by University of Sao Paulo · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies testing eszopiclone in Sleep Initiation and Maintenance Disorders — 1 open to participants now, 1 under way, none of them phase 3. Eszopiclone · Sleep Initiation and Maintenance Disorders.

Planned enrollment
15th of 40
150 · median 60
Started
2025
the only one that year
Phase 4
18 of 40
1 open now
Registered
40th of 40
by date

Among the 40 studies testing eszopiclone in Sleep Initiation and Maintenance Disorders, this one is the 15th largest by planned enrollment, is the only one that started in 2025, is one of 18 in phase 4, and was the 40th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

1 of the 40 studies testing eszopiclone in Sleep Initiation and Maintenance Disorders is open now, in 1 country.

By country, each count listing its studies:

About eszopiclone

Eszopiclone: first FDA approval 2004 (LUNESTA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing eszopiclone in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

Insomnia is a common sleep disorder characterized by difficulty falling asleep, staying asleep, or both, despite appropriate opportunities for getting sleep. Growing evidence has associated insomnia with prevalent and incidence of hypertension. However, the impact of the pharmacologic treatment of insomnia on office blood pressure (BP) and 24-h ambulatory BP monitoring (ABPM) in unclear. Therefore, the aim of this study is to evaluate the impact of eszopiclone, a non-benzodiazepine hypnotic that binds to certain subunits of the gamma-aminobutyric acid type A receptors GABA-A (such as α1, α3, and α5) promoting relaxation and sleep. Eszopiclone is an FDA-approved treatment for insomnia in those who have difficulty falling asleep and for patients with difficulty staying asleep (sleep maintenance).

Read the detailed description

We will consecutively evaluate the presence of insomnia in adult patients with hypertension under regular treatment recruited from the outpatient clinic at the Heart Institute (InCor).

The following exams will be made:

  1. Definition of the presence of insomnia following the criteria from DSM V and severity by the insomnia severity index.
  2. Evaluation of the Pittsburgh Sleep Quality Index.
  3. Evaluation of daytime sleepiness by the Epworth Sleepiness Scale.
  4. Evaluation of anxiety disorder by the Generalized Anxiety Disorder (GAD-7)
  5. Beck form for depression evaluation.
  6. Detection of sleep apnea using a portable monitor (BiologixTM) Patients that fulfilled the inclusion criteria will be submitted to a 1-month run-in period before randomization with pill counting for improving medical adherence and defining baseline BP. Then patients with be randomized to sleep hygiene + eszopiclone or sleep hygiene + placebo for 3 months (double-blind study design). We will collect demographic and anthropometric data, as well as concomitant comorbidities, medications, standard BP measurements (office and ABPM) at baseline and after 3 -months.

The main hypothesis is that pharmacological treatment, as compared to placebo, will be able to improve insomnia in parallel to a significant decrease in 24-h ABPM (primary outcome). We will also evaluate absolute decrease of daytime and nighttime BP, % of 24-h, daytime, and nighttime BP control, % non-dipping BP, office BP, sleep quality and improvement in insomnia severity index scale as secondary outcomes. Exploratory analysis evaluating the effects of eszopiclone according to the type of insomnia (initial or sleep-onset insomnia, middle or maintenance insomnia and terminal or late insomnia). We also explored whether the results will be influenced by the presence of untreated sleep apnea.

03

Conditions studied

  • Insomnia
  • Hypertension

Keywords

  • Insomnia
  • Hypertension
  • Blood Pressure
  • Treatment
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (30 to 75 years-old)
  • \<40Kg/m2;
  • Availability to participate
  • History of HBP under regular treatment (systolic pressure between 130-160 and diastolic pressure between 80-100 mmHg).

Exclusion criteria

Exclusion Criteria:

  • Use of benzodiazepines or "Z" drugs;
  • Night workers;
  • History of severe (COPD);
  • Heart failure ( \<40% on echocardiogram);
  • Prior stroke;
  • Generalized anxiety disorder (GAD-7 >14 points) and severe depression (Beck);
  • Severe liver disease;
  • Alcohol abuse;
  • Advanced chronic kidney disease 4 or 5 ( \<30ml/min/1.73m2);
  • Patient who is on loop diuretics;
  • Patient with type 1 diabetes;
  • Patient with decompensated type 2 diabetes ( >10%);
  • Urinuria Incontinence;
  • Prostatism;
  • History of active cancer;
  • Pregnancy;
  • Complex sleep behaviors, suicidal behavior.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Placebo comparator
    Placebo + sleep hygiene

    Placebo pill (identical to the active treatment) + sleep counseling for improving insomnia

    Drug: Placebo

  • Active comparator
    Eszopiclone + sleep hygiene

    Active treatment for insomnia + sleep counseling

    Drug: Eszopiclone 3 mg

Interventions

  • DrugEszopicloneStudies of EszopicloneEszopiclone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Eszopiclone is an FDA-approved treatment for insomnia in those who have difficulty falling asleep and for patients with difficulty staying asleep (sleep maintenance).

  • DrugPlacebo

    Placebo pills identical to the active comparator.

06

What researchers measure

Primary outcomes

  1. Efficacy of insomnia treatment on blood pressure (evaluated by Ambulatory blood pressure monitoring)

    To assess the impact of treatment of insomnia with eszopiclone on 24-h blood pressure by ABPM (mmHg).

    Time frame: 3 months

Secondary outcomes

  1. Efficacy of insomnia treatment on daytime and nighttime blood pressure (evaluated by Ambulatory blood pressure monitoring)

    To assess the impact of treatment of insomnia with eszopiclone on daytime and nighttime blood pressure BP (mmHg).

    Time frame: 3 months

  2. Efficacy of insomnia treatment on 24-h, daytime, and nighttime BP control (evaluated by Ambulatory blood pressure monitoring)

    To assess the impact of treatment of insomnia with eszopiclone on 24-h, daytime, and nighttime BP control (%).

    Time frame: 3 months

  3. Efficacy of insomnia treatment on non-dipping BP pattern (evaluated by Ambulatory blood pressure monitoring)

    To assess the impact of treatment of insomnia with eszopiclone on non-dipping BP (%).

    Time frame: 3 months

  4. Efficacy of insomnia treatment on blood pressure (evaluated by office blood pressure)

    To assess the impact of treatment of insomnia with eszopiclone on office BP (mmHg).

    Time frame: 3 months

  5. Efficacy of insomnia treatment on sleep quality (evaluated by Pittsburgh Sleep Quality Index)

    To assess the impact of treatment of insomnia with eszopiclone on sleep quality (absolute values).

    Time frame: 3 months

  6. Efficacy of insomnia treatment on insomnia severity (evaluated by insomnia severity index)

    To assess the impact of treatment of insomnia with eszopiclone on insomnia severity (absolute values).

    Time frame: 3 months

Other outcomes

  1. Efficacy of insomnia treatment on blood pressure based on the type of insomnia

    To assess the impact of treatment of insomnia with eszopiclone on blood pressure according to the type of insomnia (initial or sleep-onset insomnia, middle or maintenance insomnia and terminal or late insomnia).

    Time frame: 3 months

  2. Efficacy of insomnia treatment on blood pressure according to sleep apnea status

    To assess the impact of treatment of insomnia with eszopiclone on blood pressure in patients with and without sleep apnea.

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Academic Research Organization - Heart Institute (InCor)
    São Paulo, SP 05403900, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 11 months after the start.

Of 53 non-industry phase 4 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 59. This study's planned 11 months is below that.

Counting every sponsor, half of 58 studies reached it within 28 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2025
First posted
Jun 12, 2025
StartActual
Jun 4, 2025
Primary completionEst.
Jun 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07018557
Responsible party
Luciano F Drager, MD, PhD (Associate Professor of Medicine, University of Sao Paulo) — Principal investigator
First posted
Jun 12, 2025
Start date
Jun 4, 2025
Primary completion
Jun 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 12, 2025

Study contacts

LUCIANO F DRAGER, MD, PhD
Contact
luciano.drager@incor.usp.br
+5511988027887
Luciano F. Drager, MD, PhD
study chair · University of Sao Paulo Medical School

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eszopiclone

Start the discussion